A Phase 4, Randomized, Double-Blind, Study Evaluating the Safety, Efficacy and Pharmacokinetics of Idelalisib in Patients with Previously Treated Follicular Lymphoma or Small Lymphocytic Lymphoma

Trial Profile

A Phase 4, Randomized, Double-Blind, Study Evaluating the Safety, Efficacy and Pharmacokinetics of Idelalisib in Patients with Previously Treated Follicular Lymphoma or Small Lymphocytic Lymphoma

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Follicular lymphoma; Lymphoma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 17 May 2016 Status changed from recruiting to discontinued.
    • 29 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top